Page 19 - Read Online

Daniele et al. Hepatoma Res 2021;7:61 https://dx.doi.org/10.20517/2394-5079.2021.58 Page 7 of 14

INR 1.7-2.3 1 (6.3%) 0 (0.0%)
INR > 2.3 0 (0.0%) 1 (5.6%)
Morphology of hepatocellular carcinoma
Uninodular and extension ≤ 50% 2 (12.5%) 2 (11.1%)
Multinodular and extension ≤ 50% 13 (81.3%) 13 (72.2%)
Massive or extension > 50% 1 (6.3%) 3 (16.7%)
Alpha-fetoprotein
< 400 µg/L 10 (62.5%) 12 (75.0%)
≥ 400 µg/L 6 (37.5%) 6 (37.5%)
Portal vein thrombosis
No 7 (43.8%) 8 (44.4%)
Yes 9 (56.3%) 10 (62.5%)
Previous therapyΔ
Surgical resection 2 (12.5%) 0 (0.0%)
Percutaneous ethanol injection 2 (12.5%) 5 (31.3%)
Radiofrequency ablation 4 (25.0%) 6 (37.5%)
⁋
TAE/TACE 8 (50.0%) 4 (25.0%)
None 8 (50.0%) 10 (55.6%)
† ‡ § |
BSC: Best supportive care; CLIP: cancer liver Italian program; ECOG: Eastern Cooperative Oncology Group; : the same patient may have more

than one aetiologic factors; Δ: the same patient may have received more than one previous treatment; TAE/TACE : transarterial
embolization/transarterial chemoembolization.

Figure 2. Study flow.

daily rather than 800 mg. Four patients required a dose reduction during the treatment. At the time of the
analysis, all patients had discontinued sorafenib, 11 of them after one cycle. Reasons for treatment
discontinuation were progression of HCC (6 cases), toxicity (5 cases), patient refusal (3 cases, 2 of whom
with diarrhea), and worsening from Child-Pugh B to C (2 cases). Adverse events leading to treatment